This is to inform that the Board has recommended Rs. 1.50/-dividend per Equity Share for the Financial Year 2025-26
SUDEEPPHRM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.4 pts more than Nifty Microcap 250 and 1.4 pts more than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Sudeep Pharma's Board has recommended a final dividend of Rs. 1.50 per equity share (150% on face value of Rs. 1) for FY 2025-26, subject to shareholder approval at the forthcoming AGM. The company reported robust FY2025-26 results with consolidated revenue from operations of Rs. 6,422.58 crore, up 28% YoY from Rs. 5,020 crore. Consolidated profit after tax grew 25.5% to Rs. 1,742.85 crore from Rs. 1,387.29 crore. EPS improved to Rs. 15.50 per share from Rs. 12.79. The company completed its IPO in November 2025 and recently acquired Nutrition Supplier & Services (Ireland) Limited as a step-down subsidiary.
The 150% dividend payout signals financial health and shareholder-friendly policies. Combined with strong 25%+ profit growth, this could support the stock price near-term pending shareholder approval at AGM.